GlassScriptPhysician profile
Matthew Douglas Armstrong
NPI 1457363236
$2,337.65
in general payments reported to CMS, 2019-2025
21 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $469 · 2021: $366 · 2022: $325 · 2023: $258 · 2024: $313 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.46 |
| Education | $382.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $535.07 | 2019-2025 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $228.83 | 2019-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Glaxosmithkline, LLC. | $181.84 | 2021-2025 | Zejula, Jemperli |
| Astellas Pharma US INC | $159.99 | 2020-2021 | |
| Abbvie INC. | $152.78 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $114.95 | 2024-2025 | Adstiladrin |
| Seagen INC. | $95.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $64.92 | 2024 | Onivyde, Tazverik |
| Gilead Sciences, INC. | $46.58 | 2021-2025 | Trodelvy |
| Amgen INC. | $46.47 | 2019 | |
| Clovis Oncology, INC. | $29.52 | 2019 | |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Sumitomo Pharma America, INC. | $23.93 | 2023 | Orgovyx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $17.78 | 2021 | |
| Incyte Corporation | $15.28 | 2019 | |
| Daiichi Sankyo INC. | $15.14 | 2025 | Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $11.81 | 2019 | |
| Genentech USA, INC. | $11.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.